Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 1
1944 1
1945 5
1946 4
1948 1
1949 1
1951 1
1952 1
1954 1
1955 1
1968 1
1973 1
1975 1
1978 1
1979 1
1980 2
1981 2
1982 4
1983 2
1985 1
1987 2
1988 2
1989 6
1990 5
1991 2
1992 3
1993 3
1994 2
1995 2
1996 4
1997 1
1998 4
1999 4
2000 4
2001 7
2002 9
2003 10
2004 10
2005 15
2006 9
2007 8
2008 12
2009 19
2010 22
2011 35
2012 48
2013 42
2014 57
2015 24
2016 39
2017 55
2018 74
2019 94
2020 90
2021 103
2022 102
2023 111
2024 106
2025 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,177 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Among authors: shah ma. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: shah ma. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 Free PMC article. No abstract available.
Oesophageal cancer.
Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P, Cunningham D. Smyth EC, et al. Among authors: shah ma. Nat Rev Dis Primers. 2017 Jul 27;3:17048. doi: 10.1038/nrdp.2017.48. Nat Rev Dis Primers. 2017. PMID: 28748917 Free PMC article. Review.
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu CH, Doi T, Moriwaki T, Kim SB, Lee SH, Bennouna J, Kato K, Shen L, Enzinger P, Qin SK, Ferreira P, Chen J, Girotto G, de la Fouchardiere C, Senellart H, Al-Rajabi R, Lordick F, Wang R, Suryawanshi S, Bhagia P, Kang SP, Metges JP; KEYNOTE-181 Investigators. Kojima T, et al. Among authors: shah ma. J Clin Oncol. 2020 Dec 10;38(35):4138-4148. doi: 10.1200/JCO.20.01888. Epub 2020 Oct 7. J Clin Oncol. 2020. PMID: 33026938 Clinical Trial.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. Klempner SJ, et al. Among authors: shah ma. Clin Cancer Res. 2023 Oct 2;29(19):3882-3891. doi: 10.1158/1078-0432.CCR-23-0204. Clin Cancer Res. 2023. PMID: 37490286 Free PMC article. Clinical Trial.
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.
Ronellenfitsch U, Friedrichs J, Barbier E, Bass GA, Burmeister B, Cunningham D, Eyck BM, Grilli M, Hofheinz RD, Kieser M, Kleeff J, Klevebro F, Langley R, Lordick F, Lutz M, Mauer M, Michalski CW, Michl P, Nankivell M, Nilsson M, Seide S, Shah MA, Shi Q, Stahl M, Urba S, van Lanschot J, Vordermark D, Walsh TN, Ychou M, Proctor T, Vey JA. Ronellenfitsch U, et al. Among authors: shah ma. JAMA Netw Open. 2024 Aug 1;7(8):e2425581. doi: 10.1001/jamanetworkopen.2024.25581. JAMA Netw Open. 2024. PMID: 39093560 Free PMC article.
Improving outcomes in patients with oesophageal cancer.
Shah MA, Altorki N, Patel P, Harrison S, Bass A, Abrams JA. Shah MA, et al. Nat Rev Clin Oncol. 2023 Jun;20(6):390-407. doi: 10.1038/s41571-023-00757-y. Epub 2023 Apr 21. Nat Rev Clin Oncol. 2023. PMID: 37085570 Review.
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Shitara K, Xu RH, Ajani JA, Moran D, Guerrero A, Li R, Pavese J, Matsangou M, Bhattacharya P, Ueno Y, Wang X, Shah MA. Shitara K, et al. Among authors: shah ma. Gastric Cancer. 2024 Sep;27(5):1058-1068. doi: 10.1007/s10120-024-01518-1. Epub 2024 Jul 2. Gastric Cancer. 2024. PMID: 38954176 Free PMC article.
1,177 results